Hookipa Pharma (HOOK) Competitors $1.95 +0.01 (+0.52%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOOK vs. PYXS, ALXO, IMAB, RGLS, KPTI, SKYE, GNLX, EPRX, ADAG, and CUEShould you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Pyxis Oncology (PYXS), ALX Oncology (ALXO), I-Mab (IMAB), Regulus Therapeutics (RGLS), Karyopharm Therapeutics (KPTI), Skye Bioscience (SKYE), Genelux (GNLX), Eupraxia Pharmaceuticals (EPRX), Adagene (ADAG), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical preparations" industry. Hookipa Pharma vs. Pyxis Oncology ALX Oncology I-Mab Regulus Therapeutics Karyopharm Therapeutics Skye Bioscience Genelux Eupraxia Pharmaceuticals Adagene Cue Biopharma Pyxis Oncology (NASDAQ:PYXS) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Is PYXS or HOOK more profitable? Pyxis Oncology has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -36.22% -28.76% Hookipa Pharma -86.74%-33.31%-21.65% Which has more risk & volatility, PYXS or HOOK? Pyxis Oncology has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Does the MarketBeat Community believe in PYXS or HOOK? Hookipa Pharma received 63 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 82.35% of users gave Pyxis Oncology an outperform vote while only 69.47% of users gave Hookipa Pharma an outperform vote. CompanyUnderperformOutperformPyxis OncologyOutperform Votes2882.35% Underperform Votes617.65%Hookipa PharmaOutperform Votes9169.47% Underperform Votes4030.53% Which has preferable earnings & valuation, PYXS or HOOK? Pyxis Oncology has higher earnings, but lower revenue than Hookipa Pharma. Pyxis Oncology is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis OncologyN/AN/A-$73.79M-$1.03-1.46Hookipa Pharma$20.13M1.17-$81.58M-$3.72-0.52 Does the media favor PYXS or HOOK? In the previous week, Hookipa Pharma had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 1 mentions for Hookipa Pharma and 0 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.00 equaled Hookipa Pharma'saverage media sentiment score. Company Overall Sentiment Pyxis Oncology Neutral Hookipa Pharma Neutral Do insiders and institutionals have more ownership in PYXS or HOOK? 39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 9.8% of Pyxis Oncology shares are held by company insiders. Comparatively, 3.3% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend PYXS or HOOK? Pyxis Oncology presently has a consensus target price of $9.43, suggesting a potential upside of 528.57%. Hookipa Pharma has a consensus target price of $23.00, suggesting a potential upside of 1,079.49%. Given Hookipa Pharma's higher possible upside, analysts clearly believe Hookipa Pharma is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Hookipa Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryPyxis Oncology and Hookipa Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.52M$6.23B$5.21B$9.15BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-0.529.2886.8617.36Price / Sales1.17310.151,270.8879.32Price / CashN/A61.4443.7535.97Price / Book0.216.055.314.79Net Income-$81.58M$154.90M$122.62M$225.00M7 Day Performance9.55%-0.31%0.63%2.62%1 Month Performance-3.47%0.43%2.59%3.81%1 Year Performance-70.46%3.08%25.80%20.10% Hookipa Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHookipa Pharma2.4541 of 5 stars$1.95+0.5%$23.00+1,079.5%-70.5%$23.52M$20.13M-0.5256PYXSPyxis Oncology1.4814 of 5 stars$1.52-2.3%$9.43+522.3%-35.6%$90.09M$16.15M-1.4760Positive NewsALXOALX Oncology3.8616 of 5 stars$1.67-5.6%$8.50+409.0%-86.9%$88.08MN/A-0.5640Short Interest ↓Positive NewsIMABI-Mab2.8575 of 5 stars$1.06+1.0%$8.00+654.7%-30.5%$86.39M$3.27M0.00380Gap UpRGLSRegulus Therapeutics2.1981 of 5 stars$1.31-7.1%$10.80+724.4%+1.6%$85.81MN/A-1.2230Positive NewsGap DownKPTIKaryopharm Therapeutics3.996 of 5 stars$0.67-6.4%$5.00+643.2%-13.8%$84.90M$148.44M-0.59380Analyst RevisionGap DownSKYESkye Bioscience1.7454 of 5 stars$2.77-10.6%$18.67+573.9%+1.1%$84.04MN/A0.0011GNLXGenelux1.1329 of 5 stars$2.43-5.8%$18.25+651.0%-79.8%$83.93M$8,000.00-2.5610Positive NewsEPRXEupraxia PharmaceuticalsN/A$3.01+0.3%$9.00+199.0%N/A$82.12MN/A-4.1829Positive NewsADAGAdagene2.2706 of 5 stars$1.85-4.4%$5.00+170.3%-30.3%$81.90M$815,746.000.00260Short Interest ↑Positive NewsGap DownCUECue Biopharma4.2007 of 5 stars$1.29-14.9%$5.00+289.1%-53.2%$81.41M$9.53M-1.4360News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Pyxis Oncology Competitors ALX Oncology Competitors I-Mab Competitors Regulus Therapeutics Competitors Karyopharm Therapeutics Competitors Skye Bioscience Competitors Genelux Competitors Eupraxia Pharmaceuticals Competitors Adagene Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOOK) was last updated on 1/20/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts